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Abstract
H2 receptor antagonists can rarely cause idiosyncratic drug reactions leading to acute hepatitis.
Famotidine, however, is considered a relatively safe drug with regards to hepatotoxicity. We
report a case of a 47 year old male with a history of hepatitis C who developed acute hepatitis on
the third day of hospitalization with a dramatic rise in his liver enzymes from normal values at the
time of admission. The acute rise in liver enzymes made us consider an adverse drug reaction and
famotidine was discontinued. Subsequently his liver enzymes came back to normal in seven days.
Thus, physicians should consider famotidine induced hepatitis as a possible etiology of acute liver
dysfunction.
Introduction
Drug-induced hepatic injury is a very common cause of
hepatitis in adults. Drug hepatotoxicity is the most com-
mon cause of fulminant liver failure in the United States
[1]. Hepatotoxicity can occur with many drugs through a
variety of mechanisms and can present with an array of
clinical presentations ranging from asymptomatic mild
biochemical abnormalities to an acute illness that resem-
bles viral hepatitis [2,3]. A variety of drugs like acetami-
nophen, isoniazid, sulfonamides, methotrexate,
methyldopa etc. are well known to cause liver damage.
Current H2 receptor antagonists have been very rarely
associated with idiosyncratic drug reactions leading to
liver failure. In the past, two H2 receptor antagonists have
been withdrawn because of high risk of liver toxicity [4,5].
However liver toxicity has never been shown to be a class
effect of H2 receptor antagonists [6]. Cimetidine and Ran-
itidine can produce rare idiosyncratic hepatotoxic reac-
tions [6]. Famotidine, however, is considered to be a
relatively safe drug with regards to hepatotoxicity [7]. We
report a case of acute hepatic failure secondary to the use
of famotidine. To our knowledge, there have only been 4
cases in the English literature where famotidine was
responsible for hepatotoxicity [8-10].
Case presentation
A 47 year old male with a past history of asymptomatic
chronic Hepatitis C diagnosed 4 years ago, on no home
medications, came to the hospital with chief complaints
of right upper quadrant abdominal pain and vomiting for
one day. His vital signs on admission were stable. On
physical examination the abdomen was tender to palpa-
tion in right upper quadrant with no palpable organome-
galy. He had no stigmata of end stage liver disease.
Laboratory data at the time of admission showed WBC
14.5 th/mm3 (normal 4 – 11 th/mm3), Hemoglobin 16 g/
dl (normal 14 – 18 gm/dl), Platelets 190 th/mm3 (normal
130 – 400 th/mm3), Total bilirubin 0.7 mg/dl (normal 0.0
– 1 mg/dl), INR 1.4, total protein 5.3 gm/dl (normal 6.3
– 8.2 gm/dl), Albumin 2.6 gm/dl (normal 3.4 – 5 gm/dl),
AST 28 U/l (normal 15 – 37 U/l), ALT 52 U/l (normal 30
– 65 U/l), Alkaline phosphatase 99 U/l (normal 50 – 136
U/l) and a Lipase level of 174 U/l (normal 114 – 286 U/
Published: 27 January 2009
Cases Journal 2009, 2:89 doi:10.1186/1757-1626-2-89
Received: 24 November 2008
Accepted: 27 January 2009
This article is available from: http://www.casesjournal.com/content/2/1/89
© 2009 Gupta et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2009, 2:89 http://www.casesjournal.com/content/2/1/89
Page 2 of 3
(page number not for citation purposes)
l). An ultrasound of the abdomen done at the time of
admission showed a stone in the gall bladder neck with
pericholecystic fluid consistent with our clinical diagnosis
of acute cholecystitis. The patient was admitted to the hos-
pital, started on Morphine, Cefoxitin and Famotidine and
subsequently underwent laparoscopic cholecystectomy
the next day. Fentanyl, propofol and vecuronium were
used for anesthesia. His hospital course was uneventful
until the third day when he started complaining of some
abdominal pain with a change in urine color. A complete
metabolic panel was obtained on the patient at this time
which now showed AST 8466 U/l, ALT 4755 U/l, Total
bilirubin 2.5 mg/dl, INR 2.4 with a normal alkaline phos-
phatase. The sudden elevation in liver enzymes within a
couple of days of hospitalization made us think of a pos-
sible medication induced adverse reaction. The patient's
medications at that time were cefoxitin, morphine and
famotidine. Famotidine was discontinued at this time and
serial measurements of liver enzymes were done. The liver
enzymes started improving from the next day and were
back to normal within the next 7 days. (Figure 1) No fur-
ther investigations were done on the patient as the tempo-
ral association of the administration of famotidine and
elevation in liver enzymes combined with the response
demonstrated after discontinuation of famotidine was
very significant in this case.
Discussion
H2 receptor antagonists are widely used for the treatment
of peptic ulcer and gastroesophageal reflux disease. In
addition they are commonly prescribed to hospitalized
patients for stress ulcer prevention. In general they are
very well tolerated drugs and have very few side effects.
They can rarely cause adverse hepatic effects which are
mostly asymptomatic [11]. While there has been some
data regarding possible idiosyncratic reactions to cimeti-
dine and ranitidine leading to acute liver failure, no such
association has been reported to date with famotidine. In
a case-control study done by Garcia et al [6], rare adverse
hepatic reactions were seen with the use of ranitidine,
cimetidine and omeprazole but not with famotidine.
Studies done by Ohnishi [7] and Luyendyk et al [12] have
also shown famotidine to be safe with regards to hepato-
toxicity.
To our knowledge there have been four cases reported
where famotidine was responsible for hepatic failure [8-
10]. In the above mentioned four cases, hepatitis was
noted after a few weeks of famotidine. Our case is unique
in that the adverse reaction was noted within 36 hours
after the administration of famotidine.
There have been various studies which have looked at the
pharmacokinetics of famotidine following administration
to patients with concomitant liver disease including
decompensated cirrhosis [7,13,14]. Most of these studies
conclude that famotidine clearance is not altered with
impairment of hepatic function. However, one study
done by Ohnishi et al [15] showed that famotidine clear-
ance was reduced in decompensated cirrhosis. However,
that study also showed that famotidine clearance was
affected by renal function. Our patient in addition to
being Hepatitis C positive had also developed acute kid-
ney injury at the same time with a serum creatinine rising
from 0.8 mg/dl to 2.2 mg/dl (GFR 34 ml/min). His creat-
inine also returned to baseline of 1 mg/dl at 5 days. The
exact significance of this impaired renal function on the
development of acute hepatitis is unknown at this time
but it could potentially have resulted in a decreased clear-
ance of the drug and thus predisposing him to this adverse
reaction. Although just a solitary incidence, it might sug-
gest the need for a larger trial looking at the pharmacoki-
netics of famotidine in patients with combined renal and
hepatic dysfunction.
In conclusion, as famotidine is a commonly used medica-
tion both for treatment and prophylaxis, physicians need
to be aware of the possibility of this severe idiosyncratic
reaction leading to development of acute hepatitis follow-
ing administration of famotidine especially in patients
with hepatic or renal dysfunction and should promptly
discontinue the drug if famotidine induced liver toxicity is
suspected.
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Graph showing the trend of Liver Function tests in our  patient Figure 1
Graph showing the trend of Liver Function tests in 
our patient. Famotidine was stopped on day 4.
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